key: cord-0981259-vf7qlzir authors: Hopkins, Claire; Alanin, Mikkel; Philpott, Carl; Harries, Phil; Whitcroft, Katherine; Qureishi, Ali; Anari, Shahram; Ramakrishnan, Yujay; Sama, Anshul; Davies, Elgan title: Management of new onset loss of sense of smell during the COVID‐19 pandemic ‐ BRS Consensus Guidelines date: 2020-08-27 journal: Clin Otolaryngol DOI: 10.1111/coa.13636 sha: e89ba8d1e540ba3951c744a697fa4ab1599aeb1c doc_id: 981259 cord_uid: vf7qlzir OBJECTIVES: The primary aim of the study is to provide recommendations for the investigation and management of patients with new onset loss of sense of smellduring the COVID‐19 pandemic DESIGN: After undertaking a literature review, we used the RAND/UCLA methodology with a multi‐step process to reach consensus about treatment options, onward referral andimaging. SETTING AND PARTICIPANTS: An expert panel consisting of 15 members was assembled. A literature review was undertaken prior to the study and evidence was summarised for the panellists. MAIN OUTCOME MEASURES: The panel undertook a process of ranking and classifying appropriateness of different investigations and treatment options for new onset loss of sense of smell during the COVID‐19 pandemic.Using a 9‐point Likert scale, panellists scored whether a treatment was: Not recommended, optional, or recommended. Consensus was achieved when more than 70% of responses fell into the category defined by the mean. RESULTS: Consensus was reached on the majority of statements after 2 rounds of ranking. Disagreement meant no recommendation was made regarding one treatment, using Vitamin A Drops. Alpha lipoic acid was not recommended, olfactory training was recommended for all patients with persistent loss of sense of smell of more than 2 weeks duration, and oral steroids, steroid rinses and omega 3 supplements may be considered on an individual basis. Recommendations regarding the need for referral and investigation have been made. CONCLUSION: This study identified the appropriateness of olfactory training, different medical treatment options, referral guidelines and imaging for patients with COVID‐19 related loss of sense of smell. The guideline may evolve as our experience of COVID‐19 develops. At the time of writing (May 12th 2020), there have been 226,000 confirmed cases of COVID-19 in the UK. Using data available through the COVID-19 Symptom tracker which is monitoring over 2.5 million members of the public, it is estimated that there have been in excess of 2 million cases. The British Rhinological Society (BRS) and ENTUK were the first to report that loss of smell or taste may be an important symptom. There has been a rapid growth in the evidence base supporting the initial observations made by the BRS/ENTUK that an apparent rise in incidence of loss of sense of smell reflected the onset of the COVID-19 pandemic(1-3). A previously published systematic reviewsuggests a prevalence of self-reported loss of sense of smell in 50% of patients(4) with COVID-19. Emerging data suggests a high rate of early recovery, but at 4-6 weeks after onset approximately 10% patients have not experienced any recovery and still self-report severe loss of sense of smell. Applying the prevalence and recovery rates to estimated cases in the UK, there are likely already more than 100,000 new cases of severe loss of sense of smell persisting beyond the first few weeks of COVID-19infection. We do not yet know the potential for long term recovery, but we anticipate that both GPs and ENT doctors will see an increase in the number of patients presenting for advice. As there is a high rate of spontaneous recovery reported across all studies within 2 weeks of onset of symptoms therefore we will consider only patients where duration of loss or reduction of sense smell (LOS), with or without loss of sense of taste, is longer than 14 days or more. Furthermore, respiratory deterioration typically occurs between day 7 -12 after onset of symptoms and this period should be allowed to pass before considering specific treatments, particularly as the safety of treatments in the setting of severe COVID- 19 has yet to be fully established for any treatments considered. Self-reported loss of taste may be caused by either loss of flavourdue to loss of retronasal olfactory function or true loss of gustatory function. However, we will not attempt to This article is protected by copyright. All rights reserved differentiate or address this in this guidance, which will focus on self-reported loss of sense of smell. The aim of this guidance is to provide evidence-based recommendations for the management of patients with COVID-19 related loss of sense of smell, while at the same time trying to optimise use of resources but ensuring those with alternative pathologies are identified in a timely manner. As no COVID-19 specific evidence yet exists we formed an expert panel and asked them to apply their experience in interpreting the current evidence base on the management of post-viral olfactory loss. We considered both investigation of patients presenting with loss of sense of smell during the COVID-19 pandemic and management of post-COVID-19 loss of sense of smell. This article is protected by copyright. All rights reserved No formal ethical approval was required.Only CH and MA could access individual responses and group responses and comments were anonymized prior to recirculation. An expert panel of 15 members was assembled, comprising of members of the BRS Council, members of an ENTUK taskforce charged with developing guidance for outpatient practice in ENT and representatives of the Global Consortium of Chemosensory Research. The guidelines were initiated by and have been endorsed by the BRS. A comprehensive literature review has been undertaken, by CH and MA, using Medline, Cochrane databases.We searched MEdRxIv, a preprint server for evidence specific to COVID-19 but did not find any relevant studies. Evidence was summarised for the panellists (Appendix 1), this was largely derived from systematic reviews which were circulated in full to the panel with the questions in order to minimise risk of bias being introduced through the summaries produced. Studies were considered if they included any patients with post-viral olfactory loss, or idiopathic loss. Some treatments identified by the literature review were excluded if included in a systematic reviewand shown to be ineffective, if the treatment was unavailable in the UK or if the mode of administration could not be supported during the pandemic (for example, repeated intravenous administration), or if regular face to face contact was required for administration or monitoring (Appendix 2). We used the RAND/UCLA methodology, a modified Delphi communication method, where a group of experts using a multi-step process reach consensus over a series questions based on clinical scenarios.Questions were designed by CH and MA, and the evidence summaries and questions were circulated for comments to a subgroup of the panel to Accepted Article ensure that all important aspects were addressed and the questions were clearly presented prior to scoring. Our expert panel undertook a process of ranking and classifying appropriateness of different investigations and treatment options.Using a 9-point -Likert scale, panellists scored whether a treatment was: Not recommended: should not be undertaken or prescribed based on current evidence base as risks outweigh likely benefits (1 -3), Optional: could be undertaken or prescribed based on discussion with individual patient based on likely risks versus benefits (4-6), Recommended: should be undertaken or prescribed in all patients unless there are contraindications as benefits outweigh likely risks (7) (8) (9) Free text comments were encouraged if greater context was required, if questi ons were ambiguous or if any intervention or investigation had been overlooked. For each intervention or investigation, several options were given in terms of timings (eg commencing treatment at 2, 4 weeks or later). A question was posed for each intervent ion to ask if the time points given should be amended for the next round. Specific combinations of treatments were not considered as the evidence base does not currently have sufficient data to evaluate for any enhanced effectiveness when used in combination. However multiple options could be considered and recommended, and none of the treatments would be considered a contra-indication to use of any others. Upon receiving the results, the classification of recommendation was based on the mean ranking scores collated from each clinical scenario provided that there was consensus. Consensus was defined as the requirement for more than 70% of responses to fall into the category defined by the mean, and when the mean score sits in 'recommended', less than 15% of responses fall into not recommended, and vice versa. Where consensus was not reached items were reconsidered in a further round. Disagreement was declared if more than 30% of responses fell in both recommended and not recommended; in this setting no recommendation could be given. Where a recommendation was made to start treatments at several time points, the earliest point was given as a recommendation. Panellists were given 72 hours to return their answers.The scores at the end of round 1 were analysed and represented to the group, with each individual receiving a copy of their own initial evaluation. The panel was then asked to repeat the scoring for any items where consensus had not been reached. After the second round, any remaining items that had not reached consensus were further reviewed. The data generated and analysed during the study are available from the corresponding author on reasonable request. Six items reached consensus at the end of round 1. Some questions were amended for the second round in response to comments from panellists; for example, many panellists requested information on COVID-19 status and endoscopy findings in order to make recommendations.Steroid rinses were identified as a missing treatment and added. All panellists completed both rounds of the Delphi process. After the second round, consensus had been achieved on most items. There was disagreement on the use of Vitamin A drops and therefore no recommendations have been made in the guideline. In 4 areas consensus could not be achieved at the 70% threshold, but was met at 60%. Further discussion lead to consensus regarding imaging. The remaining items related to treatment using oral corticosteroids, steroid drops or rinses and omega 3 supplements. The mean score for these items was 5, and 60 -67% considered these an option, and less than 15% would not recommend. They have been included as an option but the uncertainty regarding the balance of risk and benefit should be discussed with the patient, and a decision made on an individual basis. An MRI scan of brain is recommended if endoscopy is normal Loss of smell for more than 4 -6 weeks associated with persistent nasal symptoms (regardless of COVID-19 status) Nasal endoscopy should be performed prior to imaging. However given the risks surrounding endoscopy and limited availability, imaging may be requested first in selected cases. If endoscopy is normal, further imaging is recommended (either MRI or CT). Unilateral lesions or suspicion of malignancy on endoscopy needs urgent investigation with MRI/CT. Benign findings (e.g. nasal polyps) should be treated medically before considering imaging. Loss of smell associated with neurological symptoms (excluding gustatory dysfunction) This article is protected by copyright. All rights reserved All patients with LOS more than 4 -6 weeks with additional neurological symptoms should have an MRI scan of brain regardless of prior COVID-19 status. This article is protected by copyright. All rights reserved Olfactory training and support Olfactory training is recommended to patients with LOS more than 2 weeks. It is recommended that loss of sense of smell advice is provided to the patients. It is recommended that patients are directed to AbScent and Fifth Sense for further support. It is recommended in patients with LOS more than 2 weeks associated with nasal symptoms. It is optional to recommend intranasal steroid drops or rinses in patients with LOS more than 2 weeks associated with nasal symptoms. It is not recommended to prescribe oral corticosteroids for a patient with LOS more than 2 weeks with persistent COVID-19 symptoms. It is optional to recommend oral corticosteroids for a patient with LOS more than 2 weeks as an isolated symptom or following resolution of any other COVID-19 symptoms. Due to disagreement within the group, it was not possible to make a recommendation regarding the use of Vitamin A drops. This article is protected by copyright. All rights reserved It is not recommended for a patient with LOS more than 2 weeks as an isolated symptom or following resolution of any other COVID-19 symptoms. It is optional for a patient with LOS more than 2 weeks as an isolated symptom or following resolution of any other COVID-19 symptoms. The flow chart ( Figure 1 ) summarizes key points in relation to treatment, investigations and management of new onset loss of sense of smell during the COVID-19 pandemic. *Denotes items where consensus was achieved at 60% and not the 70% threshold, highlighting ongoing uncertainty regarding usage. We therefore suggest that decisions regarding usage should be made at an individual patient level, considering the risks in view of comorbidities and individual patient preferences This article is protected by copyright. All rights reserved Discussion Postviral olfactory loss (PVOL) is one of the most common causes of olfactory dysfunction. Pathogens include those viruses causing the common cold comprising influenza-, parainfluenza-, rhino-and coronavirus (5) . Olfactory dysfunction can have a significant negative impact on quality of life (6) . COVID-19 has been shown to be associated with a high prevalence of loss of sense of smell and taste, and early reports on recovery suggest that while this may be transient in many cases, resolving in 7-14 days, at least 10% will have severe deficits lasting beyond the first 4 -6 weeks (7). Longer term data is not yet available. Historical reports of spontaneous recovery following post-viral loss likely exclude patients with transient loss due to under-reporting, but instead capture those with loss persisting at least in beyond the first few weeks. Nevertheless, two retrospective studies, including 791 and 262 patients respectively, indicate that between one third to two thirds of patients with PVOL will experience a clinically relevant improvement (6, 8, 9) . However, recovery can sometimes take several years. Given the high incidence of COVID-19 it is anticipated that both primary care and ENT specialists will see a surge in patients seeking advice. The applied RAND/UCLA methodology allowed for timely development of appropriateness criteria for the medical management, referral guidelines, endoscopy and strategies for imaging of patients with new onset loss of sense of smell. Indeed, time was the essence in this study as many doctors including general practitioners and ENT surgeons are expected to meet a significant number of patients with post-COVID-19 loss of sense of smell in the near future or in subsequent outbreaks (8) . The flow chart created should assist with overview and appropriate management. This methodology combined the best available evidence with the cooperative judgment of experts in the field. There exists solid evidence for the use of olfactory training in the treatment of PVOL (5-7). Smell training is also recommended by the expert panel in this study for the management of This article is protected by copyright. All rights reserved new onset loss of sense of smell during the COVID-19 pandemic.Many different medications have been proposed to treat PVOL, including oral corticosteroids, topical corticosteroids, zinc sulfate, alpha lipoic acid, theophylline, caroverine, vitamin A, Ginkgo biloba, sodium citrate and minocycline. However, the evidence to support use of these medical treatments for PVOL is limited and no large randomized controlled trials (RCT) exist. The expert panel only recommended use of INCS in patients with loss of sense of smell and concomitant nasal symptoms and made recommendations against the use of alpha lipoic acid. We were unable to reach consensus at the 70% threshold determined a priori but did achieve consensus at a 60% threshold for 3 treatments; topical steroid rinses, omega-3 supplements and oral corticosteroids (but only if no symptoms of COVID-19 or after full resolution of symptoms). We did agree that these could be considered as optional medical treatments, but after discussion with patients regarding the uncertainty surrounding usage and assessment of risks at an individual level. Delivery of ENT care will be challenging as we undertake a graduated return to elective practice. In particular, use of nasal endoscopy needs to be carefully considered due to its potential to be an aerosol generating procedure. Waiting times for ENT care will likely significantly increase. For many patients with confirmed COVID-19 infection and loss of sense of smell, specialist review and further investigation will not be required; however, serology testing will be required for those who had been unable to access testing at the time of active infection. We have identified those who will benefit from specialist review, and also provided supporting material to assist primary care doctors, who may have had quite limited experience in this area. We plan to develop further educational material for both GP's and ENT surgeons. Patient groups including AbScent and Fifth Sense will play an important role in patient support, we are delighted to be partnering with both groups to provide patient information leaflets (Appendix 3) and further support through a variety of different media. A strength of the method was to give each panellist an equal voice in the Delphi process, and This article is protected by copyright. All rights reserved maintaining anonymity throughout the scoring process. The methodology is also ideally suited to the social distancing requirements of the current pandemic in place of nominal group techniques where face-to-face discussion is required. A limitation is that the guidelines are based on the panellist's interpretation of the best available evidence and may be influenced by their own training and clinical experience. Another limitation may be the group composition as it is generally recommended that the group is multidisciplinary(10); it would have benefited from the inclusion of both primary care doctors and patient representatives. Limitations of the study are that the evidence base considered is not specific to COVID-19. There is a risk that bias could be introduced in the evidence summaries produced, but in order to minimise this the systematic reviews upon which these were based were circulated in full. Some treatments, shown to be ineffective In the systematic reviews were not considered and others were excluded if they were not available in the UK or safe to administer during a time of restricted access to healthcare (e.g. iv infusions, or treatments needing regular monitoring of blood levels), however, these may be available in other settings outside of the UK and as this decision was not made as part of the Delphi process it may have introduced a potential source of bias. We make no treatment recommendations for loss of less than 2 weeks -in part as many patients show rapid improvement and treatment may not be required, but patients may still seek advice and support from patient groups and there would be no harm in starting smell training at an earlier point should they wish to do so. Recommendations may need to change in the face of new evidence.We originally included a suggestion that patients with unknown COVID-19 status should have serology testing, but more recent evidence showing limitations with both false positive and false negative results (11) . Furthermore, recent evidence has shown that antibody levels decline by 70% during convalescence, such that in mild casessuch that 12% who initially seroconverted did not have detectable antibodies at 8 weeks (12) . As antibody testing is not yet widely available in the UK and this delay will further affect the value of serological testing, we have removed this recommendation. Finally, the term 'loss of sense of smell' was used in the clinical scanrios, and the panel were not asked to consider differing severity of loss. Unpublished studies show very high This article is protected by copyright. All rights reserved rates of recovery in those with mild to moderate loss at the onset of olfactory dysfunction, but these guidelines could be applied in these cases as well as patients with complete loss of smell. Future updates may consider complete and partial loss separately. We look forward to a time when the COVID-19 pandemic will pass -and these guidelines no longer be needed. They have been developed for a time when the prevalence of COVID-19 related loss of smell is high, but they will need to be reconsidered when the relative likelihoods of differential diagnoses increase -particularly with regard to indications for further imaging. Although considered with regard to COVID-19 related loss of sense of smell, the recommendations on treatments may be applied to all post-viral loss of sense of smell, although the risk -benefit analysis may need to be modified. Finally, it should be noted that as our experience of COVID-19 grows, our guideline will likely need to evolve. We hope that the newfound spotlight on loss of sense of smell and taste will drive clinical research and lead to the development of novel treatment options for patients with post-viral loss, and that greater understanding exists for those who do not recover. Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, et al. Database Syst Rev. 2020;6:CD013652. This article is protected by copyright. All rights reserved Delphi Survey There is evidence to support that olfactory training improves olfactory function in patients with PVOL. A meta-analysis in 2016 (1) Most included studies in these were prospective, without control groups, and therefore the chance of spontaneous recovery contributing to benefit shown cannot be excluded Negligibletime taken to perform In a systematic review published in 2019, it was concluded that topical steroid sprays do not improve olfactory dysfunction in non-chronic rhinosinusitis related olfactory loss(4). In the only placebo controlled RCT by there was no difference between topical nasal sprays or placebo, in a study of 40 patients, in whom 23 had PVOL (5) . Notably, all patients were pre-treated with oral prednisolone. Heilman et al reported no improvement using This article is protected by copyright. All rights reserved mometasone in 37 patients with idiopathic anosmia (6) . In a prospective study in 18 patients with mixed aetiologies were included of which eight patients had PVOL, beclomethasone spray was applied using a special applicator to direct the spray to the olfactory cleft for 4 weeks(7 One proposed mechanism for the anosmia in COVID-19 has been localized inflammation leading to obstruction of the olfactory cleft. Lechien et al. report on CT scans of 16 patients with acute onset COVID anosmia, and 60% demonstrate partial (but not complete) opacification of the olfactory cleft, but otherwise normal sinuses. There is one other report of imaging of the olfactory cleft showing complete obstruction in a single patient (10) . Topical steroids are associated with an increased risk epistaxis There is potential to increase the risk of household transmission by droplet spread if there remains a detectable viral load Many studies on systemic steroids find favourable outcomes in patients with PVOL; however, there exist no large randomized controlled studies. In addition, different regimes, drugs used and evaluation methods makes comparisons difficult. This article is protected by copyright. All rights reserved Potential to exacerbate severity of respiratory symptoms (now thought unlikely to be significant concern) or delay clearance of the virus This article is protected by copyright. All rights reserved Caution is required when interpreting studies with no control arm as spontaneous improvement rates in patients with PVOL have been reported between 35% after 12 months follow-up (14) and up to 67% after a mean follow-up of 34 months (15) . Evaluated in 23 patients with PVOL in a prospective, unblinded, uncontrolled trial by Hummel et al in 2002 (16) . Dosing was oral administration of 600 mg/d for 3 to 11 months. Olfactory function was assessed using Sniffin´Sticks. Six patients (26%) showed moderate and eight patients (35%) large increase in olfactory function. Caution is required when interpreting studies with no control arm as spontaneous improvement rates in patients with PVOL have been reported between 35% after 12 months follow-up (14) and up to 67% after a mean follow-up of 34 months (15) . Signs of low blood pressure including dizziness, headache, feeling weak, shaking There are no studies evaluating omega 3 supplements in PVOL but a prospective RCT in 87 patients undergoing endoscopic sellar and parasellar surgery, after controlling for other factors, patients receiving omega-3 had better olfactory outcomes than the control arm (17) . Animal models deficient in omega 3 demonstrate olfactory dysfunction while adults with a diet rich in omega 3 had reduced odds of developing olfactory impairment in a 5-year observational study. A dosage of 2000mg/day was used the trial above. This article is protected by copyright. All rights reserved In a reporting olfactory testing in skull base meningiomas, on half were anosmic preoperatively and the authors report that patient rarely complained of loss of sense of smell, postulating that as the loss was gradual it was overlooked (22) . This muscle-relaxing drug was used in one randomized controlled proof of concept study by Quint et al (1) in 2002. Patients with other aetiologies are included in the study making robust conclusions difficult. There were 38 of 77 total patients in the study with PVOD as the aetiology for olfactory dysfunction, but it is not specifically listed how many PVOD patients were in each treatment group. Both threshold and identification improved with the conclusion is that Caroverine may be a reasonable treatment in PVOD. It has not been possible to access the original study to confirm how the treatment was delivered, however, due to poor oral absorption it is stated in other papers that caroverine has to be given intravenously, or by continuous subcutaneous infusion, which would not be possible given the current pandemic. Ginko was used in one study as an add on to topical and oral steroids (2) , it was shown to have no additional benefit One non-randomised parallel group study showed no benefit of add on zinc to topical steroids and vitamin B alone Minocycline was evaluated in a RCT in 55 patients with PVOL but found to have no benefit over placebo (3) . Interestingly there was an improvement in TDI on Sniffin Stick scores in 15% of both groups, highlighting the need for a placebo arm, and the need for caution in interpreting non-controlled trials This article is protected by copyright. All rights reserved A number of studies have evaluated the immediate benefit of intranasal sodium citrate rinses (4, 5) , but only immediate change in thresholds, 30 -120 minutes have been evaluated and it is not clear if there is any lasting benefit beyond this. Oral theophylline has been shown to have benefit in patients hyposmia, but this was not maintained beyond the end of treatment duration (6) . Oral theophylline monitoring of levels and is associated with risks of side effects including CNS irritation, arrthymias, diarrhoea, muscle tremors and dermatitis. As these are symptoms that can present in COVID-19 it was felt that it would be difficult to both safely monitor the patient and differentiate side effects of drug from complications of the disease. Although intranasal use has also been shown to have greater effect and (7) fewer side effects, it is not available in the UK Loss of sense of smell, or anosmia, has a significant impact on quality of life. Typically it affects not only our ability to smell (both good and bad odours) but impairs our ability to detect flavours. Our sense of taste is actually pretty basicnot much more that sweet, sour, salty, bitter or 'meaty' (called umami) and this may be unaffected, although many patients also find that this can be affected after COVID- For anyone who newly develops this symptom, there is, in addition, often associated anxiety regarding the likelihood of recovery, worry about the underlying cause and sometimes lack of support and understanding from family and friends. We will try to provide some advice for anyone developing anosmia during the COVID-19 pandemic, when access to health-care may be restricted. Loss of sense of smell can occur following a head injury, in association with conditions that cause nasal obstruction (e.g. chronic sinusitis) or in some cases no specific cause is found. Loss of smell following a viral infection is the second most This article is protected by copyright. All rights reserved more than 2 weeks. This involves repeated stimulation of the smell nerves. There are some excellent resources available to help you do this; try the websites http://www.fifthsense.org.uk/smell-training or abscent.org. In the absence of essential oils, make use of pleasant odours that you find round the house, provided they are safe and in a liquid form! In terms of other treatments, the British Rhinological Society have reviewed the evidence for all treatments that have been described. One of the problems is that there has been surprisingly little research in this area in the past, and so many studies are small and we cannot be certain how reliable the findings are. We cannot make very strong recommendations regarding these treatments, but there are 3 options that might be considered; Corticosteroids tablets or drops (On prescription only); In the past, doctors have often prescribed oral steroids to try to improve recovery rates. There is uncertainty regarding whether oral steroids can delay the clearance of COVID-19 in an infected person and therefore at the moment we are advising against their use during the first two weeks following the onset of symptoms. Use may be considered as an option, but you should discuss this carefully with a doctor as there are potential side effects that should be considered. Your doctor might also consider using steroid drops or washes. Corticosteroid nasal sprays (available over the counter) Nasal steroids are unlikely to be of direct benefit, although as they have low rates of absorption into the body; if you also have a blocked nose then they are more likely to be helpful. if you take them for hayfever or other conditions, please continue to do so. Reducing sneezing and a runny nose will help reduce the risk of transmitting the virus. Omega 3 supplements (available over the counter). In addition, there is some weak evidence to support the use of omega 3 supplements in smell loss, although this has never been trialled in COVID-19 infection. They are This article is protected by copyright. All rights reserved available over the counter, but you should make sure that they don't interact with other medications before use. Don't worry if you can't get hold of any of these optionsas mentioned before, there is a good chance of recovery without these. On the positive side, if you have had COVID-19 and are making a good recovery, you will hopefully have developed some immunity which should give you some peace of mind at what is a very difficult time. However, we do not yet fully understand how good this immunity might be, and how long it will last, so please continue to take all recommended precautions with regards to regular hand washing and social distancing once your period of self-isolation is over, particularly if you have not been tested. Patients with COVID-19 are most infectious in the first week, which is why the current guidelines are for 7 days. The length of loss of smell is not related to how infectious you are, so that you do not need to worry that you may be passing on the infection to others later on, even if your sense of smell has not recovered. Please visit AbScent and Fifth Sense for additional advicefor example in keeping safe. They will also help you to connect with others who have had the same experience, which can be very helpful. Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection Clinical and Epidemiological Characteristics of 1,420 European Patients with mild-tomoderate Coronavirus Disease Real-time tracking of self-reported symptoms to predict potential COVID-19 Self-reported alteration of sense of smell or taste in patients with COVID-19: a systematic review and meta-analysis on 3563 patients Position paper on olfactory dysfunction Postinfectious olfactory loss: A retrospective study on 791 patients Early recovery following new onset loss of sense of smell during the COVID-19 pandemic -an observational cohort study Recovery of olfactory function following closed head injury or infections of the upper respiratory tract Long-term follow-up of olfactory loss secondary to head trauma and upper respiratory tract infection Effect of panel composition on appropriateness ratings Efficacy of olfactory training in patients with olfactory loss: a systematic review and meta-analysis Effects of olfactory training: a meta-analysis Olfactory Training Using Heavy and Light Weight Molecule Odors Therapeutic use of steroids in non-chronic rhinosinusitis olfactory dysfunction: a systematic evidence-based review with recommendations Placebo-controlled, randomized, double-blind study evaluating the efficacy of fluticasone propionate nasal spray for the treatment of patients with hyposmia/anosmia Local and systemic administration of corticosteroids in the treatment of olfactory loss Topical beclomethasone in the therapy of smelling disorders-a new application technique Active olfactory training for the treatment of smelling disorders Budesonide irrigation with olfactory training improves outcomes compared with olfactory training alone in patients with olfactory loss Sudden and Complete Olfactory Loss Function as a Possible Symptom of COVID-19. JAMA otolaryngology--head & neck surgery A primer on viral-associated olfactory loss in the era of COVID-19. Int Forum Allergy Rhinol Olfactory function in patients with postinfectious and posttraumatic smell disorders before and after treatment with vitamin A: a double-blind, placebo-controlled, randomized clinical trial Intranasal vitamin A is beneficial in post-infectious olfactory loss Olfactory dysfunction Long-term follow-up of olfactory loss secondary to head trauma and upper respiratory tract infection Lipoic acid in the treatment of smell dysfunction following viral infection of the upper respiratory tract Supplementation in Patients With Smell Dysfunction Following Endoscopic Sellar and Parasellar Tumor Resection: A Multicenter Prospective Randomized Controlled Trial Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms. Int Forum Allergy Rhinol What is the best imaging modality to investigate olfactory dysfunction in the setting of normal endoscopy? Cost effectiveness of magnetic resonance imaging in the workup of the dysosmia patient Routine magnetic resonance imaging for idiopathic olfactory loss: a modeling-based economic evaluation. JAMA otolaryngology--head & neck surgery Olfactory function in patients with olfactory groove meningioma The quinoxaline derivative caroverine in the treatment of sensorineural smell disorders: a proof-of-concept study Treatment of Postviral Olfactory Loss with Glococorticoids, Ginko biloba, and Mometasone Nasal Spray Treatment of postinfectious olfactory disorders with minocycline: a double-blind, placebo-controlled study A randomised controlled trial of sodium citrate spray for non-conductive olfactory disorders The effect of intranasal sodium citrate on olfaction in post-infectious loss: results from a prospective, placebocontrolled trial in 49 patients An open-label controlled trial of theophylline for treatment of patients with hyposmia. The American journal of the medical sciences Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study Accepted Article